{"member_organisations": "", "identification_number": "60329985751-43", "fields_of_interest": "General and Institutional Affairs, Economy, finance and the euro, Trade, Competition, Consumers, Education and training, Employment and Social Affairs, Energy, Business and Industry, Environment, Taxation, Youth, Single market, Research and innovation, Public Health, Digital economy and society", "head_office_address": "Riverwalk; Citywest Business Campus, 5", "full_time_equivalent_fte": "2,25", "person_with_legal_responsibility": "Flemming Ornskov", "financial_year_start_date": "01/01/2017", "grants": "", "country_code": "IE", "head_office_country": "Ireland", "eu_initiatives": "All initiatives, policies, and legislation related to the biopharmaceutical sector and patient access to innovative medicines. These include: \n \nEuropean Commission's annual work programme \nEuropean Medicines Agency \nHealthcare policies \nHealth Technology Assessment \nInnovative Medicines Initiative \nIntellectual Property \nPatient access to innovative medicines \nPatient safety \nPersonalised medicines \nPharmaceutical legislation \nPharmaceutical sector policies \nRare disease policies \nResearch & Development", "level_of_interest": "European, global, national", "organisation_name": "Shire (Shire)", "belgium_office_post_code": "1000", "procurement": "", "section": "II - In-house lobbyists and trade/business/professional associations", "lon": -6.420166399999999, "source": "", "belgium_office_address": "47, rue Montoyer", "belgium_office_phone": "(+32)2 711 02 30", "number_of_ep_accredited_persons": "", "overall_budget_turnover_as_a_range": "", "subsection": "Companies & groups", "no_geo_reference": true, "persons_accredited_for_access_to_european_parliament_premises": "", "estimate_of_costs_absolute_amount": "", "registration_date": "28/04/2011", "website_address": "http://www.shire.com/shireplc/en/home", "commission_expert_groups_and_other_similar_entities_european_commission": "NA", "head_office_post_box": "", "head_office_city": "Dublin", "membership": "European Association of Bioindustries (EuropaBio) \nEuropean Confederation of Pharmaceutical Entrepreneurs (EUCOPE)  \nEuropean Federation of Pharmaceutical Industries and Associations (EFPIA) \nPlasma Protein Therapeutics Association (PPTA) \n \nAmerican Chamber of Commerce to the European Union (AmCham EU) \nBritish Chamber of Commerce in Belgium \nEuropean Policy Centre (EPC) \nFriends of Europe", "head_office_post_code": "24", "goals__remit": "Shire is the leading global biotechnology company focused on serving people affected by rare diseases and highly specialized conditions. These diseases are often misunderstood, under-diagnosed, and potentially life-threatening. \n \nWe are dedicated to expanding, building and sustaining leadership across our key therapeutic areas through our extensive portfolio of products, innovative pipeline and collaborative approach to working with diverse partners around the globe. We strive to earn and keep the trust of our patients, their families and physicians, and all others who support and advance their care.", "industry_forums": "", "inter_groups": "", "number_of_persons_involved": "7", "relevant_communication": "EU pharmaceutical legislation. \nEuropean Commission review of intellectual property (IP) and incentives under EU legislation. \nThe evaluation of EU legislation on medicines for children and rare diseases (EU Orphan Regulation, EU Paediatric Regulation). \nFollow-up actions related to the 2009 Council Recommendation on an action in the field of rare diseases. \nDebates and initiatives on pricing of and access to medicines. \nEuropean cooperation on Health Technology Assessment.", "financial_year_end_date": "01/12/2017", "lat": 53.2899684, "estimate_of_costs_as_a_range": "600000-699999", "overall_budget_turnover_absolute_amount": "0", "legal_status": "Limited company", "person_in_charge_of_eu_relations": "Toon Digneffe", "customers": "", "belgium_office_post_box": "", "position": "Head, EU Public Affairs", "belgium_office_city": "Brussels", "head_office_phone": "(+353)1 429 7700"}